Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Non-Current Liabilities (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Other Non-Current Liabilities for 10 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 64.78% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, down 64.78% year-over-year, with the annual reading at $1.8 million for FY2025, 64.78% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $1.8 million at Akebia Therapeutics, down from $5.0 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $85.4 million in Q2 2021, with the low at $760000.0 in Q4 2022.
  • Average Other Non-Current Liabilities over 5 years is $27.6 million, with a median of $6.8 million recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities soared 4416.56% in 2021, then plummeted 99.09% in 2023.
  • Over 5 years, Other Non-Current Liabilities stood at $1.8 million in 2021, then tumbled by 58.24% to $760000.0 in 2022, then changed by 0.0% to $760000.0 in 2023, then skyrocketed by 581.05% to $5.2 million in 2024, then crashed by 64.78% to $1.8 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $1.8 million, $5.0 million, and $14.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.